



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Donald L. MORTON *et al.*

Serial No.: 07/431,533

Filed: November 3, 1989

For: URINARY TUMOR ASSOCIATED
ANTIGEN, ANTIGENIC SUBUNITS
AND METHODS OF DETECTION

[illegible]

Group Art Unit: 1813

Examiner: H. Sidberry

Atty. Dkt.: CADL:002/PAR

COMMUNICATION

Assistant Commissioner for Patents
Washington, D.C. 20231


Dear Sir:

This communication supplements the transitional response and amendment, filed on September 30, 1996, regarding the above-captioned application. Applicants request that the examiner accept the enclosed Declaration of Ralph A. Reisfeld Under 37 C.F.R. § 1.132 for consideration.

In his declaration, Dr. Reisfeld provides further reasons why the Euhus *et al.* abstract, currently advanced by the examiner under 35 U.S.C. §102 and §103, is not enabling for the claimed subject matter. In particular, Dr. Reisfeld points out that the absence of a meaningful description of U-TAA, or an antibody thereto, would preclude the skilled artisan for confirming that the work described by Euhus *et al.* had, in fact, been reproduced. Without this ability, the value of the Euhus *et al.* disclosure to the present invention is nil.

Consideration of the enclosed declaration and comments included herein is respectfully requested prior to a first Office Action. While applicants believe no fees are due at this time, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Arnold, White & Durkee Deposit Account No. 01-2508/CADL:002/PAR.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642

ARNOLD, WHITE & DURKEE
P.O. Box 4433
Houston, Texas 77210
(512) 418-3000

Attorney for Applicants

Date: December 18, 1996